Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Collyar: What's In It for Patients?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Sep

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Collyar: What's In It for Patients?

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Prostate Cancer Cardiovascular Risk Factors May Help Identify Patients Who Would Benefit From Additional Cardiac Care

Investment in Blood Cancer Research Has Saved Nearly 26 Million Years of Life, but Major Gaps in Survival Remain

Cervical Cancer Nonscreening Increased Over Nearly 2 Decades

Predictors of pCR to Neoadjuvant THP Explored in HER2-Positive Breast Cancer

Prostate Cancer NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT